Metrics as of 10/15/2026, 11:32 PM (Berlin time), refresh in progress.
Alto Neuroscience Stock
Alto Neuroscience, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Amit Etkin
- Employees
- 68
- Market cap
- $888 M
- IPO
- 02/02/2024
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress…
Alto Neuroscience stock: price history
1D
+4.2%
1W
-5.9%
1M
-25.2%
6M
-13.2%
YTD
+27.1%
1Y
+270.2%
2Y
+59.7%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~23% weaker price swings than usual
Alto Neuroscience stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Alto Neuroscience is a clinical-stage biopharmaceutical company dedicated to developing innovative medications for psychiatric disorders. The company focuses on treating diseases such as major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and schizophrenia. A central pillar of its business model is an advanced, AI-powered biomarker platform that enables the analysis of patient profiles based on brain activity and behavioral patterns to identify the most promising therapeutic approaches for specific patient populations. The focus lies on various drug candidates in clinical trials as well as the development of synergistic drug combinations.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Alto Neuroscience
Analyst assessment of Alto Neuroscience
PRICE TARGET LOW
US$24.00
CONSENSUS
US$38.00
MEDIAN
US$36.50
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 17/08/2026
Alto Neuroscience stock metrics
P/E
-9.12
P/B
4.42
EV/EBITDA
-8.01
RETURN ON EQUITY
-12.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.6%
FLOAT SHARES
35,552,954
AVG. DAILY VOLUME (30D)
644,915
Insider transactions (SEC)
Smith Nicholas Conrad
Smith Nicholas Conrad
Smith Nicholas Conrad
Smith Nicholas Conrad
Smith Nicholas Conrad
Institutional holders
Comparable stocks
Frequently asked questions about Alto Neuroscience stock
What does Alto Neuroscience do?
Alto Neuroscience, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Amit Etkin, the company employs around 68 people.
The IPO was on 02/02/2024; the stock trades on NYSE under the ticker ANRO.
What do analysts say about Alto Neuroscience stock?
9 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$38.00, ranging from US$24.00 to US$55.00, with a median of US$36.50.
This is an external assessment, not a statement by Market Jury.
When does Alto Neuroscience report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -23% stronger than usual.
Does Alto Neuroscience pay a dividend?
No, Alto Neuroscience currently does not pay a dividend.
Which stocks are comparable to Alto Neuroscience?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Alto Neuroscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alto Neuroscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.